Popular on Rezul
- Amid Controversy with The Weeknd/Playboi Carti and Buzz Surrounding His Upcoming Project, Darrin Jones Drops Soulful New Single "Under Control"
- For Saving Home Services Inc: Easy-Approval HVAC Financing in Toronto for Affordable Furnace
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Rainbow Property Maintenance Launches Cost-Effective, High-Quality Medical Cleaning Services
- Steve Nosrat Joins The Mogharebi Group to Lead Las Vegas Office
- First-Time Homebuyers Face Challenges as Starter Homes Disappear in 2025
- Titan Pressure Washing Selected a 2024 Nextdoor Neighborhood Faves for Best Pressure Washing Service
- ®Grammy Award Winner Alex Cuba releases new single "El Día Más Triste"
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners
- Country Creek Condominium Chooses Corner Property to Manage its Picturesque Residential Community
Similar on Rezul
- MSM Advisors CPAs and Small Business Advisors Recognized as 'Among the Best of Gwinnett' in 2024
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
- Maryland Bill Aims to Curb Mental Health Youth Transport Abuses
- Aterna AI Introduces Automated Investing Software for Entrepreneurs Focused on Reliable Growth
- Global Digital Currency & Wealth Management Leader; Breakout 388% FY2025 Revenue Growth Over $19.7 Million: Metalpha Technology (Stock Symbol: MATH)
- Talent Concierge® Artists Agency and The Big Talk® Announce Game-Changing Partnership Challenging Status Quo in the Meetings Industry
- Partnerships to Launch Digital Entertainment Hub in China; $40 Million Investment into Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- Ceramic Liberty Unveils CL8Y: A Revolutionary Deflationary Memecoin Set to Redefine DeFi
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
Planned Spin-Out to Focus on Gene Therapy for Type 1 and 2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex: Stock Symbol: GNPX
Rezul News/10678698
Genprex Stock Symbol: GNPX is Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes
AUSTIN, Texas - Rezul -- Genprex, Inc. (Stock Symbol: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Rezul News
Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
On September 4th GNPX announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). This decision was made public on September 4, 2024.
The planned spin-out transaction would allow both GNPX and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The GNPX spin-out, would result in NewCo focusing on developing GPX-002, while GNPX would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates a strong ongoing commitment to the GNPX streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024.
The GNPX goal for separating the diabetes clinical development program from its oncology program follows closely behind a recent announcement to re-focus the GNPX oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, GNPX continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, GNPX is considering various strategic alternatives and opportunities to enhance stockholder value.
Presentations to Highlight Gene Therapies for Cancer and Diabetes
GNPX has announced its participation in the following upcoming investor and industry conferences:
More on Rezul News
Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)
Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
To watch the video, visit the GNPX website at: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Rezul News
- New Estate Agency Set To Shake Up Gosforth Property Market
- Winter Weather Woes? Triple Diamond Construction Offers Free Roof Assessments for OKC Homeowners
- Lennar opens a new model home at TrailMark
- Unlock the Hidden Power of Dreams in The Lucid War Chronicles
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
On September 4th GNPX announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). This decision was made public on September 4, 2024.
The planned spin-out transaction would allow both GNPX and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The GNPX spin-out, would result in NewCo focusing on developing GPX-002, while GNPX would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates a strong ongoing commitment to the GNPX streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024.
The GNPX goal for separating the diabetes clinical development program from its oncology program follows closely behind a recent announcement to re-focus the GNPX oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, GNPX continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, GNPX is considering various strategic alternatives and opportunities to enhance stockholder value.
Presentations to Highlight Gene Therapies for Cancer and Diabetes
GNPX has announced its participation in the following upcoming investor and industry conferences:
More on Rezul News
- Hardwood or Tile? A Homeowner's Guide to Choosing the Right Flooring
- Explore the "Magic of Rainbows" in the New Children's Book Series "Mila and Ally's STEMventures
- Integrity Storage Group Appoints Greg Head as Chairman of the Board
- Victoria Crossing Welcomes Corner Property Management as New Partner in Community Excellence
- Relentless 2800 Challenge: A 40-Day Team Fitness Journey Launching for Lent 2025
Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)
Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
To watch the video, visit the GNPX website at: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on Rezul News
- Popular Senior Housing Series Continues
- RNGD Opens New Headquarters Campus, Connecting Construction Operations, Manufacturing Operations and Training Center
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity
- Zezgo Rent A Car has arrived In Cyprus to Improve Car Rental Options
- Meredith Thomas Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Kim Estes Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Fire and Rescue Statistics Highlight Ongoing Fire Risks in UK Homes
- Andre Kay Honored with Black Excellence Award by the Florida Panthers
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- RE/MAX Evergreen Welcomes New Brokers Joaquin and Rebecca Robideau
- Volante of Hanover Expands with the Opening of Its Second Building, Introduces Assisted Living Services
- Summerwoods Parrish Florida - Community Open House on Sunday, February 16th from 12-2 PM
- Talent Concierge® Artists Agency and The Big Talk® Announce Game-Changing Partnership Challenging Status Quo in the Meetings Industry
- FlyBright Pilot Academy Partners with Allegiant Air to Address the Pilot Shortage
- Spacious 5-Bedroom Home on 3 Acres in Locust Grove, GA – Open House This Sunday
- BEPeterson Building Engineering Partnerships
- WonderDays: The Startup Disrupting the UK Gifting Industry
- Minnesota Real Estate Agent Promotes New Target Marketing
- RE1 Advisor Expands Services to Texas